Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin
Hisao Imai1, Kyoichi Kaira2, Keita Mori3, Nodoka Watase4, Takeshi Hisada5, Masanobu Yamada5, Koichi Minato1
1 Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma 373-8550; Departments of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan 2 Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan 3 Clinical Research Support Center, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 4 Division of Pharmacy, Gunma Prefectural Cancer Center, Ohta, Gunma 373-8550, Japan 5 Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan
Correspondence Address:
Hisao Imai, Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ohta, Gunma 373-8550 Japan
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jcrt.JCRT_1170_16
|